Mel-Mont Medical has developed a new preventive comprehensive diagnostic system for cervical cancer called Mía by XytoTest.

The new system comes with a medical device that enables self-collection of cervical cells in any setting without assistance.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The collected sample is later analysed to identify human papillomavirus (HPV) using a molecular system of real-time polymerase chain reaction (PCR).

The same cells can also be used for a progressive protein analysis to identify the potential risk of high-grade lesions (CIN 2+) or cervical cancer in samples of high-risk HPV positive.

Mel-Mont Medical chief operating officer Frank Meléndez said: “The idea for Mía by XytoTest arose from the need to raise awareness on the importance of the culture of self-care and prevention to fight diseases with high morbidity and mortality rates that are paradoxically preventable, such as cervical cancer.”

“The idea for Mía by XytoTest arose from the need to raise awareness on the importance of the culture of self-care and prevention to fight diseases with high morbidity and mortality rates.”

The test is based on the discovery by German doctor Harald Zur Hausen that HPV causes cervical cancer.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Mel-Mont Medical chief executive officer Liliana Montes said: “We created Mía by XytoTest to reduce sociocultural barriers that prevent the participation of women in the organised screening programmes of cervical cancer, giving them the possibility of obtaining their sample from the comfort of their home or in the doctor’s office without the need for professional assistance.”

The comprehensive system is expected to improve gynaecological intervention, prevent unnecessary deaths and provide better population coverage to prevent cervical cancer.

As compared to the Pap smear test with 30%-50% sensitivity, the new preventive diagnostic system is claimed to hold 96% sensitivity in the results.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact